The Food and Drug Administration (FDA) published a notice in the Federal Register stating that it has reopened the comment period on the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. The notice initially appeared in the Federal Register on April 3, 2019, at which time the comments were set to close on July 2, 2019.
On June 20, 2019, a notice that appeared in the Federal Register extended the comment period to July 16, 2019. Now, the FDA has extended the comment period “indefinitely.”
“In light of the continued interest and increased research activity in this space, as well as the need for additional scientific data on this topic, we have decided to reopen the comment period and extend it indefinitely to allow interested parties to continue to comment and to provide relevant data to the agency on this subject,” wrote the FDA in the notice. “If, in the future, we decide to close the comment period, we will publish a Federal Register notice to that effect. This extension will allow stakeholders to continue to provide new and emerging information, in as close to real-time as possible, as research in this area evolves.”
The FDA is particularly interested in data that may help to address uncertainties and data gaps related to the safety of cannabidiol (CBD).